{
  "docId": "019de076-f497-7249-9bc1-6e417e62b814",
  "docSlug": "fb4563ff56b082126dc8200b1dba24d8",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 23 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 23,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines the study design for a Phase Ia trial and explains why safety data is critical for the PDE10 inhibitor class.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f497-7249-9bc1-6e417e62b814/14",
  "deckHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814",
  "deckJsonHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814.json",
  "deckAnchorHref": "/decks/019de076-f497-7249-9bc1-6e417e62b814#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "Study enrolled healthy volunteers aged 18-65 years in a single centre study in the UK (HMR, London); SAD / MAD cohorts will each enrol 8 subjects (6 active, 2 placebo per cohort) with 6 SAD cohorts and 2 MAD cohorts; MAD section (Part C) will dose subjects for 14 consecutive days (BID)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a6c9aef-375b-4710-8af4-b120c1cd84c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.36
      },
      "kind": "list",
      "text": "Part A: Single Ascending Dose (SAD) | Part B: Food Effect | Part C: Multiple Ascending dose (MAD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5ba97c8-19a8-444b-8482-0baf355ab0bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.74
      },
      "kind": "list",
      "text": "PDE10s previously studied for CNS indications - failed to progress due to dose limiting CNS mediated side effects; A clean safety profile through SAD and MAD doses will be a big step forward for the use of PDE10 inhibitors as a therapeutic treatment; Results from this study will inform the preferred dose for the next stage of development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8426405-73ea-4632-a154-b1dd70bb318f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Study objectives: assess the safety and tolerability of single and multiple oral doses, and the effect of food on pharmacokinetic profile of BEN-8744 in healthy volunteer subjects",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6bf00b6-c38b-4438-9368-b0c2484e0788",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-8744 nearing completion of Phase Ia Topline data expected end Q1 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c470ab17-e820-4775-894a-e8a8ca4909dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "title",
      "text": "Importance of Phase Ia results",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddc1cd15-6d39-48e0-b658-d473e2629c65",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 8,
      "beatId": "f2ab71c9-53f6-440d-9d03-02e61c9ddb19",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Discussion of pipeline progression, strategic collaborations, and financial highlights",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "423b3a2a-1477-48ad-8005-2c65d02aa02b",
      "evidence": "Problem statement and key messages about BEN-8744",
      "position": 0,
      "objective": "Highlighting the need for BEN-8744 in ulcerative colitis treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 23,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b0e19ace-ba0d-475a-81b8-bb29008de35f",
      "evidence": "The deck's overall narrative and key takeaways",
      "position": 1,
      "objective": "Communicating the why, how, and what of BenevolentAI's AI-driven drug discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}